Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
View all episodes
